Fecal Indole as a Biomarker of Susceptibility to Cryptosporidium Infection - PubMed
- ️Fri Jan 01 2016
Fecal Indole as a Biomarker of Susceptibility to Cryptosporidium Infection
Cynthia L Chappell et al. Infect Immun. 2016.
Abstract
Cryptosporidium causes significant diarrhea worldwide, especially among children and immunocompromised individuals, and no effective drug treatment is currently available for those who need it most. In this report, previous volunteer infectivity studies have been extended to examine the association between fecal indole and indole-producing (IP) gut microbiota on the outcome of a Cryptosporidium infection. Fecal indole concentrations (FICs) of 50 subjects and 19 taxa of common gut microbiota, including six IP taxa (11 subjects) were determined in stool samples collected before and after a challenge with Cryptosporidium oocysts. At the baseline, the mean FIC (± the standard deviation) was 1.66 ± 0.80 mM in those who became infected after a challenge versus 3.20 ± 1.23 mM in those who remained uninfected (P = 0.0001). Only 11.1% of the subjects with a FIC of >2.5 mM became infected after a challenge versus 65.2% of the subjects with a FIC of <2.5 mM. In contrast, the FICs of infected subjects at the baseline or during diarrhea were not correlated with infection intensity or disease severity. The relative abundances (percent) of Escherichia coli, Bacillus spp., and Clostridium spp. were greater ≥2.5-fold in volunteers with a baseline FIC of >2.5 mM, while those of Bacteroides pyogenes, B. fragilis, and Akkermansia muciniphila were greater in those with a baseline FIC of <2.5 mM. These data indicate that some IP bacteria, or perhaps indole alone, can influence the ability of Cryptosporidium to establish an infection. Thus, preexisting indole levels in the gut join the oocyst dose and immune status as important factors that determine the outcome of Cryptosporidium exposure.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
Figures

FICs in healthy adults at stage 1 (before or within 48 h of a challenge) and outcomes of a challenge with Cryptosporidium oocysts. (A) Cumulative percent infection was calculated as described previously (40) and plotted against the mean indole concentration. The number of subjects at each indole concentration stratum is in parentheses. (B) The indole concentrations and outcome categories of the subjects are shown. The mean indole concentration ± the standard error of the mean are indicated for the infected (oocysts plus diarrhea; n = 18) and uninfected (no oocysts or diarrhea; n = 32) challenge outcome groups. Outcome groups were compared by using the Mann-Whitney test (P = 0.0001).

Fecal bacteria associated with protection from Cryptosporidium infection. Species with ≥2.5-fold difference in %RA are shown. Stool samples from healthy adults were collected prior to (or within 48 h of) exposure to Cryptosporidium oocysts. The median %RAs of the infected (Inf; n = 6) and uninfected (Uninf; n = 5) outcome groups are shown. IP bacteria include those in panels A and B.

Fecal bacteria associated with susceptibility to Cryptosporidium infection. Species with ≥2.5-fold difference in %RA are shown. Stool samples from healthy adults were collected prior to (or within 48 h of) exposure to Cryptosporidium oocysts. The median %RAs of the infected (Inf; n = 6) and uninfected (Uninf; n = 5) outcome groups are shown. IP bacteria include those in panels A to C.
Similar articles
-
Bellosa ML, Nydam DV, Liotta JL, Zambriski JA, Linden TC, Bowman DD. Bellosa ML, et al. J Parasitol. 2011 Apr;97(2):349-51. doi: 10.1645/GE-2475.1. Epub 2010 Oct 8. J Parasitol. 2011. PMID: 21506794
-
The infectivity of Cryptosporidium parvum in healthy volunteers.
DuPont HL, Chappell CL, Sterling CR, Okhuysen PC, Rose JB, Jakubowski W. DuPont HL, et al. N Engl J Med. 1995 Mar 30;332(13):855-9. doi: 10.1056/NEJM199503303321304. N Engl J Med. 1995. PMID: 7870140
-
[Human cryptosporidiosis and Cryptosporidium spp. in Haiti].
Raccurt CP, Brasseur P, Verdier RI, Li X, Eyma E, Stockman CP, Agnamey P, Guyot K, Totet A, Liautaud B, Nevez G, Dei-Cas E, Pape JW. Raccurt CP, et al. Trop Med Int Health. 2006 Jun;11(6):929-34. doi: 10.1111/j.1365-3156.2006.01631.x. Trop Med Int Health. 2006. PMID: 16772015 French.
-
Nachipo P, Hermann D, Quinnan G, Gordon MA, Van Voorhis WC, Iroh Tam PY. Nachipo P, et al. Trials. 2018 Aug 23;19(1):456. doi: 10.1186/s13063-018-2846-6. Trials. 2018. PMID: 30139372 Free PMC article.
-
Microbiome diversity is a modifiable virulence factor for cryptosporidiosis.
Hurle GR, Brainard J, Tyler KM. Hurle GR, et al. Virulence. 2023 Dec;14(1):2273004. doi: 10.1080/21505594.2023.2273004. Epub 2023 Nov 10. Virulence. 2023. PMID: 37872759 Free PMC article. Review.
Cited by
-
Deprivation of dietary fiber enhances susceptibility of mice to cryptosporidiosis.
Oliveira BCM, Bresciani KDS, Widmer G. Oliveira BCM, et al. PLoS Negl Trop Dis. 2019 Sep 27;13(9):e0007411. doi: 10.1371/journal.pntd.0007411. eCollection 2019 Sep. PLoS Negl Trop Dis. 2019. PMID: 31560681 Free PMC article.
-
Shrestha A, Metzler-Zebeli BU, Karembe H, Sperling D, Koger S, Joachim A. Shrestha A, et al. Front Microbiol. 2020 May 19;11:983. doi: 10.3389/fmicb.2020.00983. eCollection 2020. Front Microbiol. 2020. PMID: 32508791 Free PMC article.
-
Vélez J, Silva LMR, Gärtner U, Daugschies A, Mazurek S, Hermosilla C, Taubert A. Vélez J, et al. Biology (Basel). 2021 Sep 26;10(10):963. doi: 10.3390/biology10100963. Biology (Basel). 2021. PMID: 34681062 Free PMC article.
-
Funkhouser-Jones LJ, Xu R, Wilke G, Fu Y, Shriefer LA, Makimaa H, Rodgers R, Kennedy EA, VanDussen KL, Stappenbeck TS, Baldridge MT, Sibley LD. Funkhouser-Jones LJ, et al. bioRxiv [Preprint]. 2023 May 25:2023.05.25.542157. doi: 10.1101/2023.05.25.542157. bioRxiv. 2023. PMID: 37292732 Free PMC article. Updated. Preprint.
-
Williams LM, Cao S. Williams LM, et al. Pharmacol Ther. 2024 Apr;256:108605. doi: 10.1016/j.pharmthera.2024.108605. Epub 2024 Feb 16. Pharmacol Ther. 2024. PMID: 38367866 Review.
References
-
- Platts-Mills JA, Babji S, Bodhidatta L, Gratz J, Haque R, Havt A, McCormick BJ, McGrath M, Olortegui MP, Samie A, Shakoor S, Mondal D, Lima IF, Hariraju D, Rayamajhi BB, Qureshi S, Kabir F, Yori PP, Mufamadi B, Amour C, Carreon JD, Richard SA, Lang D, Bessong P, Mduma E, Ahmed T, Lima AA, Mason CJ, Zaidi AK, Bhutta ZA, Kosek M, Guerrant RL, Gottlieb M, Miller M, Kang G, Houpt ER, MAL-ED Network Investigators. 2015. Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED). Lancet Glob Health 3:e564–75. doi:10.1016/S2214-109X(15)00151-5. - DOI - PMC - PubMed
-
- Checkley W, White AC Jr, Jaganath D, Arrowood MJ, Chalmers RM, Chen XM, Fayer R, Griffiths JK, Guerrant RL, Hedstrom L, Huston CD, Kotloff KL, Kang G, Mead JR, Miller M, Petri WA Jr, Priest JW, Roos DS, Striepen B, Thompson RC, Ward HD, Van Voorhis WA, Xiao L, Zhu G, Houpt ER. 2015. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for Cryptosporidium. Lancet Infect Dis 15:85–94. doi:10.1016/S1473-3099(14)70772-8. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous